Potential advantages of CD1-restricted T cell immunotherapy in cancer

M Consonni, P Dellabona, G Casorati

Research output: Contribution to journalArticle

Abstract

Adoptive cell therapy (ACT) using tumor-specific “conventional” MHC-restricted T cells obtained from tumor-infiltrating lymphocytes, or derived ex vivo by either antigen-specific expansion or genetic engineering of polyclonal T cell populations, shows great promise for cancer treatment. However, the wide applicability of this therapy finds limits in the high polymorphism of MHC molecules that restricts the use in the autologous context. CD1 antigen presenting molecules are nonpolymorphic and specialized for lipid antigen presentation to T cells. They are often expressed on malignant cells and, therefore, may represent an attractive target for ACT. We provide a brief overview of the CD1-resticted T cell response in tumor immunity and we discuss the pros and cons of ACT approaches based on unconventional CD1-restricted T cells. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)200-208
Number of pages9
JournalMolecular Immunology
Volume103
DOIs
Publication statusPublished - 2018

Fingerprint

Immunotherapy
T-Lymphocytes
Cell- and Tissue-Based Therapy
Neoplasms
CD1 Antigens
Tumor-Infiltrating Lymphocytes
Genetic Engineering
Antigen Presentation
Immunity
Lipids
Antigens
Therapeutics
Population

Cite this

Potential advantages of CD1-restricted T cell immunotherapy in cancer. / Consonni, M; Dellabona, P; Casorati, G.

In: Molecular Immunology, Vol. 103, 2018, p. 200-208.

Research output: Contribution to journalArticle

@article{9d05667b40b342ac9d88c33c483fd191,
title = "Potential advantages of CD1-restricted T cell immunotherapy in cancer",
abstract = "Adoptive cell therapy (ACT) using tumor-specific “conventional” MHC-restricted T cells obtained from tumor-infiltrating lymphocytes, or derived ex vivo by either antigen-specific expansion or genetic engineering of polyclonal T cell populations, shows great promise for cancer treatment. However, the wide applicability of this therapy finds limits in the high polymorphism of MHC molecules that restricts the use in the autologous context. CD1 antigen presenting molecules are nonpolymorphic and specialized for lipid antigen presentation to T cells. They are often expressed on malignant cells and, therefore, may represent an attractive target for ACT. We provide a brief overview of the CD1-resticted T cell response in tumor immunity and we discuss the pros and cons of ACT approaches based on unconventional CD1-restricted T cells. {\circledC} 2018 Elsevier Ltd",
author = "M Consonni and P Dellabona and G Casorati",
year = "2018",
doi = "10.1016/j.molimm.2018.09.025",
language = "English",
volume = "103",
pages = "200--208",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Potential advantages of CD1-restricted T cell immunotherapy in cancer

AU - Consonni, M

AU - Dellabona, P

AU - Casorati, G

PY - 2018

Y1 - 2018

N2 - Adoptive cell therapy (ACT) using tumor-specific “conventional” MHC-restricted T cells obtained from tumor-infiltrating lymphocytes, or derived ex vivo by either antigen-specific expansion or genetic engineering of polyclonal T cell populations, shows great promise for cancer treatment. However, the wide applicability of this therapy finds limits in the high polymorphism of MHC molecules that restricts the use in the autologous context. CD1 antigen presenting molecules are nonpolymorphic and specialized for lipid antigen presentation to T cells. They are often expressed on malignant cells and, therefore, may represent an attractive target for ACT. We provide a brief overview of the CD1-resticted T cell response in tumor immunity and we discuss the pros and cons of ACT approaches based on unconventional CD1-restricted T cells. © 2018 Elsevier Ltd

AB - Adoptive cell therapy (ACT) using tumor-specific “conventional” MHC-restricted T cells obtained from tumor-infiltrating lymphocytes, or derived ex vivo by either antigen-specific expansion or genetic engineering of polyclonal T cell populations, shows great promise for cancer treatment. However, the wide applicability of this therapy finds limits in the high polymorphism of MHC molecules that restricts the use in the autologous context. CD1 antigen presenting molecules are nonpolymorphic and specialized for lipid antigen presentation to T cells. They are often expressed on malignant cells and, therefore, may represent an attractive target for ACT. We provide a brief overview of the CD1-resticted T cell response in tumor immunity and we discuss the pros and cons of ACT approaches based on unconventional CD1-restricted T cells. © 2018 Elsevier Ltd

U2 - 10.1016/j.molimm.2018.09.025

DO - 10.1016/j.molimm.2018.09.025

M3 - Article

VL - 103

SP - 200

EP - 208

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

ER -